News from debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 16, 2015, 08:00 ET

Debiopharm International SA Acquires FibroTrap Sample Processing Technology from Spinomix

  - Applicable to a wide variety of sample types to isolate bacteria, viruses, tumor cells, etc.  - FibroTrap improves...

Jun 16, 2015, 08:00 ET

Debiopharm International SA fait l'acquisition de la technologie de traitement des échantillons FibroTrap de Spinomix

  - Applicable à divers types d'échantillons pour isoler des bactéries, virus, cellules tumorales,...

May 19, 2015, 03:00 ET

Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)

Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or...

May 19, 2015, 03:00 ET

Debiopharm International SA annonce des résultats de phase III positifs pour le traitement de la puberté précoce centrale (PPC) par une formulation 6 mois de triptoréline

L'essai de phase III avec la formulation 6 mois de triptoréline a permis de démontrer son efficacité en termes de suppression...

Apr 23, 2015, 02:30 ET
Apr 23, 2015, 02:30 ET

Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today...

Apr 16, 2015, 08:00 ET

Debiopharm International SA annonce les résultats de deux programmes clés en oncologie à la conférence de l'AACR 2015

Debiopharm présente les résultats précliniques concernant deux thérapies anticancéreuses ciblées, Debio 1143 et...

Apr 16, 2015, 08:00 ET

Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company...

Apr 16, 2015, 08:00 ET

Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference

 Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company...

Jan 13, 2015, 10:00 ET

Debiopharm Diagnostics mène un tour d'investissement dans la société GenePOC avec Emerillon Capital

GenePOC est une société canadienne qui a développé une plateforme de diagnostics moléculaires (MDx) rapide, innovante et...

Jan 13, 2015, 10:00 ET

Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, which is developing a highly...

Jan 12, 2015, 02:30 ET

Debiopharm Group™ récupère les droits complets du programme sur l'Alisporivir

- Novartis restitue l'Alisporivir (DEB025) à Debiopharm Group™ , y compris tous les droits pour le virus de l'hépatite C et...

Jan 12, 2015, 02:30 ET

Debiopharm Group™ Regains Full Rights to Alisporivir Program

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement...

Jan 08, 2015, 03:00 ET

La FDA accorde la désignation Fast Track à l'antibiotique Debio 1450 de Debiopharm Group

- Le Debio 1450, un inhibiteur de FabI administré par voie orale/IV actif contre toutes les espèces de staphylocoques, a reçu la...

Jan 08, 2015, 03:00 ET

FDA Grants Fast Track Designation to Debiopharm Group's Antibiotic Debio 1450

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US...

Nov 18, 2014, 07:00 ET

Debiopharm Group™ Presents Advances of two key Oncology Clinical Programs at the 26th EORTC-NCI-AACR Symposium in Barcelona

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companion...

Oct 07, 2014, 08:00 ET

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 30, 2014, 08:00 ET

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now...

Sep 26, 2014, 03:00 ET

Presented by the Japanese Cancer Association and Debiopharm Group™, the 'JCA-Mauvernay Award 2014' goes to Doctors Hara and Shibata

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 17, 2014, 03:00 ET

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to congratulate Biocartis commitment in shipping its first...